نتائج البحث - Erkut Bahceci

  • يعرض 1 - 12 نتائج من 12
تنقيح النتائج
  1. 1
    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib حسب Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations حسب Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study حسب Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study

    Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study حسب Kensuke Usuki, Toru Sakura, Yukio Kobayashi, Toshihiro Miyamoto, Hiroatsu Iida, Satoshi Morita, Erkut Bahceci, Masahito Kaneko, Mikiko Kusano, Shunsuke Yamada, Shigeru Takeshita, Shuichi Miyawaki, Tomoki Naoe

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease

    Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease حسب Partow Kebriaei, Luis Isola, Erkut Bahceci, Kent Holland, Scott D. Rowley, Joseph P. McGuirk, Marcel P. Devetten, Jan Jansen, Roger H. Herzig, Michael Schuster, Rod Monroy, Joseph P. Uberti

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations حسب Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason E. Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

    Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Pa... حسب Jordi Esteve, Rik Schots, Teresa Bernal, Je‐Hwan Lee, Eunice S. Wang, Shira Dinner, Mark D. Minden, Olga Salamero, Jorge Sierra, Goichi Yoshimoto, Kamel Laribi, Janusz Hałka, Pau Montesinos, Shufang Liu, Elizabeth Rich, Erkut Bahceci

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) حسب Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

    Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor حسب Angela James, Catherine C. Smith, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman, Dale R. Shepard, Takeshi Kadokura, Kinya Souda, Melanie Patton, Zheng‐Rong Lu, Chaofeng Liu, Selina Moy, Mark J. Levis, Erkut Bahceci

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

    Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation حسب Richard Childs, Allen Chernoff, Nathalie Contentin, Erkut Bahceci, David S. Schrump, Susan F. Leitman, Elizabeth J. Read, John F. Tisdale, Cynthia E. Dunbar, W. Marston Linehan, Neal S. Young, Emmanuel Clave, Diane E. Epperson, Virginia Mayo, A. John Barrett

    منشور في 2000
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

    Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study حسب Alexander E. Perl, Jessica K. Altman, Jorge E. Cortés, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, David F. Claxton, Harry P. Erba, Stan Gill, Stuart L. Goldberg, Joseph G. Jurcic, Richard A. Larson, Chaofeng Liu, Ellen K. Ritchie, Gary J. Schiller, Alexander I. Spira, Stephen A. Strickland, Raoul Tibes, Celalettin Üstün, Eunice S. Wang, Robert K. Stuart, Christoph Röllig, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark J. Levis

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML

    Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML حسب Alexander E. Perl, Giovanni Martinelli, Jorge E. Cortés, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R. Baer, Richard A. Larson, Celalettin Üstün, Francesco Fabbiano, Harry P. Erba, Antonio Di Stasi, Robert K. Stuart, Rebecca L. Olin, Margaret Kasner, Fabio Ciceri, Wen‐Chien Chou, Nikolai A. Podoltsev, Christian Récher, Hisayuki Yokoyama, Naoko Hosono, Sung‐Soo Yoon, Je‐Hwan Lee, Timothy S. Pardee, Amir T. Fathi, Chaofeng Liu, Nahla Hasabou, Xuan Liu, Erkut Bahceci, Mark J. Levis

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: